

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, D. C. 20549

---

**FORM 8-K**

**CURRENT REPORT  
Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

**April 27, 2018**

Date of Report (Date of earliest event reported)

**ABBOTT LABORATORIES**

(Exact name of registrant as specified in charter)

---

**Illinois**

(State or other Jurisdiction  
of Incorporation)

**1-2189**

(Commission File Number)

**36-0698440**

(IRS Employer  
Identification No.)

---

**100 Abbott Park Road**

**Abbott Park, Illinois 60064-6400**

(Address of principal executive offices)(Zip Code)

Registrant's telephone number, including area code: **(224) 667-6100**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

**Item 5.07 — Submission of Matters to a Vote of Security Holders.**

Abbott held its Annual Meeting of Shareholders on April 27, 2018. The following is a summary of the matters voted on at that meeting.

- (1) The shareholders elected Abbott's entire Board of Directors. The persons elected to Abbott's Board of Directors and the number of shares cast for, the number of shares withheld, and the number of broker non-votes, with respect to each of these persons, were as follows:

| <u>Name</u>            | <u>Votes For</u> | <u>Votes Withheld</u> | <u>Broker Non-Votes</u> |
|------------------------|------------------|-----------------------|-------------------------|
| Robert J. Alpern, M.D. | 1,310,927,186    | 19,098,268            | 226,634,924             |
| Roxanne S. Austin      | 1,268,068,024    | 61,957,430            | 226,634,924             |
| Sally E. Blount, Ph.D. | 1,318,171,199    | 11,854,255            | 226,634,924             |
| Edward M. Liddy        | 1,295,334,980    | 34,690,474            | 226,634,924             |
| Nancy McKinstry        | 1,317,659,954    | 12,365,500            | 226,634,924             |
| Phebe N. Novakovic     | 1,305,047,201    | 24,978,253            | 226,634,924             |

|                     |               |            |             |
|---------------------|---------------|------------|-------------|
| William A. Osborn   | 1,288,267,458 | 41,757,996 | 226,634,924 |
| Samuel C. Scott III | 1,288,857,580 | 41,167,873 | 226,634,924 |
| Daniel J. Starks    | 1,317,385,198 | 12,640,256 | 226,634,924 |
| John G. Stratton    | 1,320,912,106 | 9,113,348  | 226,634,924 |
| Glenn F. Tilton     | 1,266,616,454 | 63,409,000 | 226,634,924 |
| Miles D. White      | 1,262,425,572 | 67,599,882 | 226,634,924 |

- (2) The shareholders ratified the appointment of Ernst & Young LLP as Abbott’s auditors. The number of shares cast in favor of the ratification of Ernst & Young LLP, the number against, the number abstaining, and the number of broker non-votes were as follows:

| <b>For</b>    | <b>Against</b> | <b>Abstain</b> | <b>Broker Non-Votes</b> |
|---------------|----------------|----------------|-------------------------|
| 1,540,591,644 | 13,002,291     | 3,066,443      | 0                       |

- (3) The shareholders voted to approve the compensation of Abbott’s named executive officers listed in the proxy statement for the 2018 annual meeting, with 78.28 percent of the votes cast voting “For” the proposal. The shareholder vote is advisory and non-binding. The number of shares cast in favor of approval, the number against, the number abstaining, and the number of broker non-votes were as follows:

| <b>For</b>    | <b>Against</b> | <b>Abstain</b> | <b>Broker Non-Votes</b> |
|---------------|----------------|----------------|-------------------------|
| 1,041,167,404 | 279,530,367    | 9,327,683      | 226,634,924             |

2

- (4) The shareholders rejected a shareholder proposal requesting that Abbott’s Board of Directors adopt a policy that the Board Chairman be an independent director, with 30.76 percent of the votes cast voting “For” the proposal. The number of shares cast in favor of the shareholder proposal, the number against, the number abstaining, and the number of broker non-votes were as follows:

| <b>For</b>  | <b>Against</b> | <b>Abstain</b> | <b>Broker Non-Votes</b> |
|-------------|----------------|----------------|-------------------------|
| 409,080,027 | 912,026,962    | 8,918,465      | 226,634,924             |

3

#### SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

#### ABBOTT LABORATORIES

Date: April 30, 2018

By: /s/ Brian B. Yoor  
 Brian B. Yoor  
 Executive Vice President, Finance  
 and Chief Financial Officer

4